Comparative Pharmacology
Head-to-head clinical analysis: CEFADYL versus KEFLIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFADYL versus KEFLIN.
CEFADYL vs KEFLIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bactericidal; inhibits cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and autolysin activation.
Cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and autolysin activation, leading to cell lysis.
1-2 g IV/IM every 6 hours for moderate to severe infections; maximum 12 g/day.
1-2 g IV/IM every 4-6 hours; maximum 12 g/day.
None Documented
None Documented
30-60 minutes in adults with normal renal function; prolonged to 10-20 hours in end-stage renal disease. Requires dose adjustment for CrCl <30 mL/min.
Terminal elimination half-life: 0.5-1 hour (normal renal function); prolonged to 2-3 hours in anuria. Clinically, dosing every 6 hours is recommended.
Renal: 90-95% unchanged via glomerular filtration and tubular secretion. Biliary: <1%. Fecal: minimal.
Renal: 70-80% unchanged via glomerular filtration and tubular secretion; biliary: minimal (<5%); fecal: <1%.
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic